The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 22, 2024
Filed:
Jan. 25, 2019
Sorbonne Universite, Paris, FR;
Ctre Recherche Pathologies Prostatiques, Paris, FR;
Ligue Nationale Contre Le Cancer, Paris, FR;
Assistance Publique Hopitaux DE Paris, Paris, FR;
Inserm (Institut National DE LA Santé ET DE LA Recherche Médicale), Paris, FR;
Université DE Tours, Tours, FR;
Centre Hospitalier Régional Universitaire DE Tours, Tours, FR;
Olivier Cussenot, Paris, FR;
Aurélie Kamoun, Paris, FR;
Aurélien De Reynies, Paris, FR;
Géraldine Cancel-Tassin, Soisy-sur-Seine, FR;
Gaëlle Fromont-Hankard, Luynes, FR;
SORBONNE UNIVERSITE, Paris, FR;
CTRE RECHERCHE PATHOLOGIES PROSTATIQUES, Paris, FR;
LIGUE NATIONALE CONTRE LE CANCER, Paris, FR;
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, Paris, FR;
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Paris, FR;
UNIVERSITÉ DE TOURS, Tours, FR;
CENTRE HOSPITALIER RÉGIONAL UNIVERSITAIRE DE TOURS, Tours, FR;
Abstract
A method for predicting the risk of prostate cancer recurrence in a subject affected with prostate cancer, including: (a) providing a sample from the subject, (b) determining the TMPRSS/ERG fusion status of the sample, (c) if the sample is positive for TMPRSS/ERG fusion (Fus), determining a molecular signature of the sample by measuring the expression level of at least 6 prostate cancer markers selected from the ANPEP, AZGP1, CHRNA2, COMP, KHDRBS3 and SFRP4, (d) comparing the molecular signature to a reference signature, and (e) assigning the subject to a risk group based on the correlation of the molecular signature with the reference signature, thereby predicting the risk of cancer recurrence in the subject.